Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Peer Review reports

Original Submission
13 Jun 2017	Submitted	Original manuscript
4 Aug 2017	Reviewed	Reviewer Report - David Rey
13 Sep 2017	Reviewed	Reviewer Report - Delphine Sculier
10 Oct 2017	Author responded	Author comments - Nicola Gianotti
Resubmission - Version 2
10 Oct 2017	Submitted	Manuscript version 2
27 Oct 2017	Reviewed	Reviewer Report - Delphine Sculier
6 Nov 2017	Author responded	Author comments - Nicola Gianotti
Resubmission - Version 3
6 Nov 2017	Submitted	Manuscript version 3
Publishing
12 Nov 2017	Editorially accepted
16 Nov 2017	Article published	10.1186/s12879-017-2831-9

Back to article page